10 Best Healthcare Penny Stocks to Buy According to Analysts

3. Nuvation Bio Inc. (NYSE:NUVB)

Stock Price as of June 27: $1.97

Analyst Upside Potential as of June 27: 275.63%

Number of Hedge Fund Holders as of Q1 2025: 34

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation’s stock on June 25. The analyst also kept the price target at $6.00 per share.

Tuerkcan’s decision follows Nuvation’s detailed presentation of launch plans for its cancer treatment, IBTROZI (taletrectinib). The drug has received FDA approval for adults with locally advanced or metastatic ROS1-positive Non-Small Cell Lung Cancer (NSCLC). China’s National Medical Products Administration (NMPA) also approved it earlier in January 2025 for the same indication. Nuvation plans to price the treatment at $29,844 per month.

Tuerkcan’s research note pointed out that IBTROZI maintains an approximately two-year lead over Nuvalent’s (NASDAQ:NUVL) zidesamtinib in front-line treatment for ROS1-positive NSCLC. She also noted that the potent efficacy of both IBTROZI and zidesamtinib is expected to drive physician interest in new ROS1 TKI treatments and expand the ROS1 class of therapies.

Nuvation Bio Inc. (NYSE:NUVB) is a clinical-stage biopharmaceutical company. It develops targeted cancer therapies for patients with tumors that are difficult to treat. Its lead product is IBTROZI. Other pipeline candidates include safusidenib (for brain tumors with IDH1 mutations), NUV-1511 (a drug-drug conjugate for solid tumors), and NUV-868 (a BET inhibitor targeting BRD4).